Immunoglobulin: Production, mechanisms of action and formulations

Revista Brasileira de Hematologia e Hemoterapia

Volumn 33, Issue 5, 2011, Pages 377-382

  Novaretti, Marcia Cristina Zago ^a   Dinardo, Carla Luana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antibodies; Hemoderivate drugs; Immune system; Immunoglobulins; Intravenous pharmacokinetics; Intravenous therapeutic use; Plasma

Indexed keywords

EID: 82855180189     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20110102     Document Type: Review

References (26)

1. Von Behring E, Kitasato S. Über das zustandekommen der diphtherieimmunität und der tetanus-immunität bei tieren. Dtsch Med wochenschr. 1890;16:1113-4.
2. Cohn EJ. Blood proteins and their therapeutic value. Science. 1945;101(2612):51-6.
3. Cohn EJ, Hughes WL Jr, Weare JH. Preparation and properties of serum and plasma proteins; crystallization of serum albumins from ethanol water mixtures. J Am Chem Soc. 1947;69(7):1753-61.
4. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008;28(4):737-64, viii.
5. Provan D, Nokes TJ, Agrawal S, Winer J, Wood P, Group IGDGotIEW. Clinical guidelines for immunoglobulin use. 2nd ed. London: Department of Health; 2008.
6. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Diretriz para transfusão de imunoglobulinas [Internet]. Brasília: ANVISA; 2004. [cited 2008 Jan 12]. Available from: http://www4.anvisa.gov.br/base/visadoc/CP/CP%5B7489-5-0%5D.PDF
7. Farcet MR, Planitzer CB, Stein O, Modrof J, Kreil TR. Hepatitis A virus antibodies in immunoglobulin preparations. J Allergy Clin Immunol. 2010;125(1):198-202.
8. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98(1):12-28.
9. Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety. Biotechnol J. 2006;1(2):148-63. Comment in: Biotechnol J. 2006;1(2):111.
10. Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs. 2005;28(6):366-74.
11. Shah SR. A newer immunoglobulin intravenous (IGIV)-Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care. Expert Opin Biol Ther. 2008;8(6):799-804.
12. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25(11 Pt 2):78S-84S.
13. Oh DJ, Lee YL, Kang JW, Kwon SY, Cho NS, Kim IS. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus]. Korean J Lab Med. 2010;30(1):45-50. Korean.
14. Poelsler G, Berting A, Kindermann J, Spruth M, Hammerle T, Teschner W, et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang. 2008;94(3):184-92.
15. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet. 1983;2(8356):974-5.
16. Dichtelmuller HO, Biesert L, Fabbrizzi F, Gajardo R, Groner A, von Hoegen I, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion. 2009; 49(9):1931-43.
17. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. Blood Transfus. 2009;7(3):216-34.
18. Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP, et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med. 2005;5(4):135-40.
19. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13(3):108-16.
20. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010;30 Suppl 1:S4-8.
21. Crow AR, Brinc D, Lazarus AH. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost. 2009;7 Suppl 1:245-8.
22. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH 17 cells by intravenous immunoglobulin. J Allergy Clin Immunol. 2011;127(3):823-30, e 1-7.
23. Navarrete MA, Salas A, Palacios L, Marin JF, Quiralte J, Florido JF. [Latex allergy]. Farm Hosp.2006;30(3):177-86. Spanish.
24. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Bulário eletrônico: imunoglobulina humana. [Internet]. Brasília: ANVISA. [cited 2010 Jan 12]. Available from: http://www4. anvisa. gov.br/base/visadoc/BM/BM[34162-1-0].PDF
25. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução RDC n°46 de 18 de maio de 2000. Aprova regulamento técnico para a produção e controle de qualidade de hemoderivados de uso humano. Brasília: Anvisa. [cited 2010 Jan 12]. Available from: http://www.anvisa.gov.br/legis/resol/2000/46_00rdc.htm
26. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. 2008;28(4): 765-78, viii.